89% of employees would recommend working at Sangamo Therapeutics to a friend and 75% have a positive outlook for the business. Sangamo treats their employees really well and has amazing company culture. Some details of my previous projects. This rating has been stable over the past 12 months. The decrease of $2.1 million in revenues was primarily attributable to a decrease of $1.9 million and $1.6 million related to our collaboration agreements with Novartis and Biogen respectively, and a decrease of $1.1 million due to the termination of our collaboration agreement with Sanofi. Some details of my previous projects. How many more words to count? Manufacturing of product candidates using improved methods progressed in the Phase 1/2 study. A pivotal readout is expected in the first half of 2024. Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and second quarter 2022 financial results. Interviews at Sangamo Therapeutics Experience Positive 38% Negative 44% Neutral 19% Getting an Interview Applied online 33% Employee Referral 25% Recruiter 17% Difficulty 2.8 Average Hard Average Easy Interviews for Top Jobs at Sangamo Therapeutics Project Manager (1) Technician (1) Scientist II (1) Bioinformatics Analyst I (1) Started with phone interview, and email communication, then few weeks later come back to schedule a zoom interview with hiring manager, during the interview where asking questions about what I know about company, my introduction, my experiences, my salary expectation. I wasn't happy with the unprofessional manner. Progressed clinical activities in preparation for the third patient. We plan to complete dosing of the first cohort, comprised of three patients, by the end of 2022. 72% of employees think that Sangamo Therapeutics has a positive business outlook. We have raised approximately $75.1 million in net proceeds under our at-the-market offering program from January 1, 2022 through October 31, 2022. Presented seven posters and one oral presentation at ASGCT on. Guided by Science. The increase of $1.5 million in revenues was primarily attributed to an increase of $1.3 million in revenue related to our collaboration agreement with Novartis and an increase of $0.8 million in revenue related to our collaboration agreement with Sanofi. However, after the last interview I haven't heard back from them. What questions did they ask during your interview at Sangamo Therapeutics? Gene editing is a very compelling concept for physicians. Employees also rated Sangamo Therapeutics 4.1 out of 5 for work life balance, 4.5 for culture and values and 3.8 for career opportunities. I wasn't happy with the unprofessional manner. Reviews 5.0 1 reviews 5.0 Career Growth 5.0 Work - Life Balance 4.0 Compensation / Benefits 5.0 Company Culture 4.0 Management POPULAR 4.0 "Great overall biotech company" While not required, it is recommended you join 10 minutes prior to the event start. "We made meaningful progress advancing our clinical-stage programs in the second quarter," said Sandy Macrae, Chief Executive Officer of Sangamo. Copyright 20082023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. Sangamo BioSciences, Inc. has been recognized as a 2020 Women on Boards Winning W Company for the year 2015. Minimum 15 minutes delayed. Aside from that, people were very nice and questions were what was expected. A replay will be available following the conference call, accessible under Events and Presentations. These decreases were partially offset by a $1.9 million adjustment to revenue during 2021 related to the collaboration agreement with Sanofi and an increase of $0.5 million in revenue related to our collaboration agreement with Kite. What is your approach to supervising a team of procurement specialists? ET to review its fourth quarter and full year 2022. Candidates give an average difficulty score of 2.8 out of 5 (where 5 is the highest level of difficulty) for their job interview at Sangamo Therapeutics. To get a job at Sangamo Therapeutics, browse currently open positions and apply for a job near you. Financial Guidance for 2022 Narrowed (initial guidance provided on February 24, 2022). Salary expectation. They said they get tested for Sars once a week, which is great too. Non-GAAP operating expenses, which exclude stock-based compensation expense, for the third quarter ended September 30, 2022 were $73.5 million, compared to $69.1 million for the same period in 2021. Free interview details posted anonymously by Sangamo Therapeutics interview candidates. Our scientists are leaders in the. We have excluded stock-based compensation expense because it is a non-cash expense that may vary significantly from period to period as a result of changes not directly or immediately related to the operational performance for the periods presented. May 26, 2020. While not required, it is recommended you join 10 minutes prior to the event start. We believe that this non-GAAP financial measure, when considered together with our financial information prepared in accordance with GAAP, can enhance investors and analysts ability to meaningfully compare our results from period to period and to our forward-looking guidance, and to identify operating trends in our business. These forward-looking statements include, without limitation, statements relating to: the therapeutic and commercial potential of our product candidates and their ability to generate value for our shareholders, the anticipated plans and timelines of Sangamo and our collaborators for screening, enrolling and dosing patients in and conducting our ongoing and potential future clinical trials and presenting clinical data from our clinical trials, including plans to dose patients in the expansion phase of, and the presentation of updated clinical data from, the Phase 1/2 STAAR study and updates regarding the PRECIZN-1 study, the dosing of patients with product candidates using improved manufacturing methods in the PRECIZN-1 study and the potential impacts thereof, as well as the timing and expectations for completion of dosing in such study, the expected timeline for dosing additional patients in the STEADFAST study, the anticipated advancement of our product candidates to late-stage development including potential future Phase 3 trials, plans and timing regarding the expected resumption of dosing of patients in the Phase 3 AFFINE trial and the presentation of data from such trial, our 2022 financial guidance related to GAAP and non-GAAP total operating expenses and stock-based compensation, and other statements that are not historical fact. BRISBANE, Calif., February 22, 2023--SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS, BRISBANE, Calif., February 22, 2023--Sangamo Therapeutics Announces Evidence of Clinical Benefit in Phase 1/2 STAAR Study in Fabry Disease. The process took 3 months. Benefits are great. Phase 3 enabling activities and manufacturing readiness are in progress. Our rare disease clinical programs are feeding insights across our portfolio and paving the way for research and preclinical programs across larger patient populations. Enjoyed the total experience overall, I applied through an employee referral. We continue to actively prepare for a potential pivotal Phase 3 trial. Candidates interviewing for Project Manager Biotech and Research Intern rated their interviews as the hardest, whereas interviews for Project Manager and Bioinformatics Analyst I roles were rated as the easiest. HR screen is just going over the Job Description and why Sangamo. Technical assay related questions? Analyst Report: Alnylam Pharmaceuticals, Inc. Analyst Report: BioMarin Pharmaceutical Inc. NasdaqGS - NasdaqGS Real Time Price. We are committed to translating ground-breaking science into genomic therapies that transform patients lives. Hemophilia A Announced, with Pfizer, the resumption of recruitment in the Phase 3 AFFINE trial; dosing is expected to resume shortly; pivotal data read-out expected in the first half of 2024. No post about Sangamo Therapeutics, Inc. yet, Hemophilia Market to Showcase Robust Growth in the Upcoming Year to 2032 | MobileODT, Gals Bio Ltd, DiagnoseSt, Global mRNA Vaccine Market Size And Forecast | Argos Therapeutics BioNTech AG, CureVac AG, eTheRNA Immunotherapies, Ethris GmbH, Incellart, Moderna Sangamo Therapeutics Tiba Biotech, Translate Bio, Inc. Sioux City Catholic Globe, We don't have enough salaries for My three times follow-up with two different HR reps was left unanswered. Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Due to the split at Richmond and Brisbane, there was confusion on which site to interview. This press release contains forward-looking statements regarding our current expectations. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected. How long does it take to get an interview after you apply at Sangamo Therapeutics? We made meaningful progress advancing our clinical-stage programs in the second quarter, said Sandy Macrae, Chief Executive Officer of Sangamo. Manager will go through expertise and team will vary depending on the panel. Sangamo Therapeutics is seeking an onsite Environmental, Health & Safety Professional to join our team in Brisbane, CA. Renal Transplant Rejection Dosed the second patient in the Phase 1/2 STEADFAST study; progressed clinical activities in preparation for patient three. Glassdoor has 55 Sangamo Therapeutics reviews submitted anonymously by Sangamo Therapeutics employees. Enzyme replacement therapy (ERT) withdrawal was completed for an additional two patients previously dosed in the STAAR study, achieving a total of four patients to date who have successfully been withdrawn. All five patients who began the dose escalation pha. Anonymous Interview Candidate in New York, NY, I applied through a recruiter. The process took 4 weeks. The average Sangamo Therapeutics salary ranges from approximately $88,067 per year for a Research Associate II to $240,483 per year for an Associate Director. Interview difficulty. Favorable. Super friendly working environment and very nice people. Conference Call and Webcast Scheduled for 4:30 p.m. Eastern Time BRISBANE, Calif. --(BUSINESS WIRE)--Feb. 22, 2023-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and fourth quarter and full year 2022 financial results. Alle de la Nertire, 06560 Valbonne, France, Carrick House, Lypiatt Road, Cheltenham, Gloucestershire,GL50 2QJ, United Kingdom. 89% of employees would recommend working at, According to anonymously submitted Glassdoor reviews, Sangamo Therapeutics employees rate their compensation and benefits as 4.0 out of 5. The interview was timely, provided an overview of the company and of the role, asked the candidate to go over their relevant career trajectory and competences. We encourage investors to carefully consider our results under GAAP, as well as our supplemental non-GAAP financial information, to more fully understand our business. I interviewed at Sangamo Therapeutics in Aug 2020, Nice set of interviews and great questions. Available materials will be found on the Sangamo Therapeutics website after the event. Fabry disease Received endorsement to progress into the Ph1/2 studys expansion phase; continued to recruit patients and activate sites; Phase 3 planning progresses. Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2022 Financial Results News Release Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Showing Continued Tolerability and Sustained Elevated -Gal A Enzyme Activity in Nine Patients News Release Good, great, fine, virtual, lovely. There is a unified sense of purpose. The process took 3 months. Why Sangamo? These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. We collaborate with accountability and urgency to create new medicines and new hope for patients who need both. Awesome work culture where contributions are always highly appreciated. Based on 2 interviews. Tell me a little about your self. As we look to next year and beyond, I am confident in Sangamos ability to carry out our mission of developing transformational therapies for patients in need.. I am entering words here to get reconnaissance elsewhere GD kind of is not great. However, I never hear back from them since then. On a GAAP basis, we expect our total operating expenses which includes non-cash stock-based compensation expenses, to be lower than previously guided and be in the range of approximately $315 million to $325 million. Total operating expenses on a GAAP basis for the third quarter ended September 30, 2022 were $81.3 million, compared to $77.0 million for the same period in 2021. In June, the Safety Monitoring Committee endorsed progressing the Phase 1/2 STAAR study evaluating isaralgagene civaparvovec, our wholly owned gene therapy product candidate for the treatment of Fabry disease, from the dose escalation phase into the expansion phase at the dose level of 5e13 vg/kg. There can be no assurance that we and our collaborators will be able to develop commercially viable products. My three times follow-up with two different HR reps was left unanswered. Glassdoor has millions of jobs plus salary information, company reviews, and interview questions from people on the inside making it easy to find a job thats right for you. Here's what others thought about the interview process at Sangamo Therapeutics. Participants should register for, and access, the call using this link. Overall, 89% of employees would recommend working at Sangamo Therapeutics to a friend. Duties of the advertised position and the involved project. Management is very accessible. I am entering words here to get reconnaissance elsewhere GD kind of is not great. Currency in USD, Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies. Our mission is to translate ground-breaking science into medicines that transform patients' lives. Actual results may differ materially from those projected in these forward-looking statements due to the risks and uncertainties described above and other risks and uncertainties that exist in the operations and business environments of Sangamo and our collaborators. We have a robust preclinical pipeline with programs in emerging areas that could provide value in the mid-to-long term. Under the general direction of the EHS Director, this role will have operational responsibility for EHS support to labs, facilities and manufacturing and shall assist with planning, establishing, implementing, and maintaining a variety of occupational health, safety, and . Conference Call and Webcast Scheduled for 4:30 p.m. Eastern Time. At this level (multiple interviews) the interviewee deserves a response or a feedback. The process took 3 days. Preliminary data showed all nine patients from the dose escalation phase exhibited sustained elevated -Gal A activity, ranging from nearly 2-fold to 30-fold of mean normal, for up to 23 months post dosing, as of the last date of measurement. Duties of the advertised position and the involved project. This is based on 44 anonymously submitted reviews on Glassdoor. Were pioneering the future of genomic medicine, Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results, Sangamo Therapeutics Announces Evidence of Clinical Benefit in Phase 1/2 STAAR Study in Fabry Disease. BRISBANE, Calif.--(BUSINESS WIRE)--Aug. 4, 2022-- All content is posted anonymously by employees working at Sangamo Therapeutics. A pivotal data readout is estimated in late 2023 or early 2024. Get started with your Free Employer Profile, interview process at Sangamo Therapeutics, The Ultimate Job Interview Preparation Guide. Skip to main navigation Science Overview Zinc Finger Cell Therapy Genome Regulation Bioethics Find your private company bowl on Fishbowl, join the hottest conversation with your colleagues anonymously. Be the first to find this interview helpful. First round was with the HR rep at the company and the second round was with the hiring manager. Research calls posted earlier this morning are available here. To learn more, visit www.sangamo.com and connect with us on LinkedIn and Twitter. Sangamo Therapeutics saw global potential for TxCell's lead candidate TX200 as the anchor of a pipeline of chimeric antigen receptor . "This has been a year marked by progress across our pipeline. Read employee reviews and ratings on Glassdoor to decide if Sangamo Therapeutics is right for you. Since we dosed the first patient in the Phase 1/2 STEADFAST study evaluating TX200, our wholly owned autologous CAR-Treg cell therapy treating patients receiving an HLA-A2 mismatched kidney from a living donor, the product candidate continues to be generally well tolerated, with no treatment related adverse events. Glassdoor has millions of jobs plus salary information, company reviews, and interview questions from people on the inside making it easy to find a job thats right for you. Sangamo Therapeutics has an overall rating of 4.2 out of 5, based on over 55 reviews left anonymously by employees. These improved manufacturing methods have been shown in internal experiments to increase the number of long-term progenitor cells in the final product. Over 50% of the patients have been enrolled in the Phase 3 AFFINE trial. Would never interview here again, HR screen, Manager, Team. I interviewed at Sangamo Therapeutics in Jul 2021. This employer has claimed their Employer Profile and is engaged in the Glassdoor community. We were proud to present promising updated preliminary data from our wholly owned Fabry study, to resume our partnered Hemophilia A pivotal trial, and to continue dosing in our renal transplant rejection and sickle cell studies. February 14, 2022. We are engaging in pivotal study-enabling activities in two of our clinical stage programs and are preparing to complete dosing of the first cohort in our TX200 program, which recently received Orphan Medicinal Product Designation from the European Commission. Sangamo Therapeutics is a genomic medicine company focused on leveraging our novel platforms and scientific expertise to advance clinical programs. Be the first to find this interview helpful. Coworkers are all very helpful and friendly. Our platforms have yielded multiple clinical stage programs that could provide value in the near-to-mid-term. We are passionate about our science and driven by the purpose it serves. Hemophilia A Pfizer advised us that it continues to expect resumption of dosing in Q3 2022; pivotal data read-out expected in late 2023 or early 2024. Claim your Free Employer Profile. Tell me about yourself? Background and experience. Pfizer advised us that it continues to anticipate resuming the dosing of additional patients in the Phase 3 AFFINE trial of giroctocogene fitelparvovec, an investigational gene therapy we are developing with Pfizer for patients with moderately severe to severe hemophilia A, in the third quarter of 2022. These risks and uncertainties are described more fully in our Securities and Exchange Commission filings and reports, including in our Annual Report on Form 10-K for the year ended December 31, 2021, as supplemented by our Quarterly Report on Form 10-Q for the quarter ended September 30, 2022. Pays significantly less than South San Francisco companies. Company is very dedicated to patient engagement as well as inclusion and diversity.Read More. Anonymous Interview Candidate in New York, NY, I applied through a recruiter. View all news about Sangamo Therapeutics, Inc. Each step toward the possibility of eliminating the need for frequent, life-long treatment for the patients and families affected by debilitating disease is exciting. Since the beginning of the second quarter, we have raised approximately $43.1 million in net proceeds under our previously announced at the market offering program. Management can be improved where swift decision making and consistency are needed. 38% of job seekers rate their interview experience at Sangamo Therapeutics as positive. Questions asked were appropriate and aimed at confirming the candidate possesses the required skills and would be a good fit into the company. Glassdoor users rated their interview experience at. Filler, words, noun, verb, et cetera. BRISBANE, Calif.--(BUSINESS WIRE)--Nov. 3, 2022-- I am able to speak with VPs of many different departments with ease. Unorganized at best. We expect to present updated data from the Phase 1/2 ALTA study via a poster presentation at the ASH Annual Meeting in December. Sangamo Therapeutics, Inc.(Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and second quarter 2022 financial results. We continue to actively prepare for a potential pivotal Phase 3 trial. Brisbane, California, November 16, 2022 Dosing has resumed in the Phase 3 AFFINE study evaluating giroctocogene fitelparvovec, an investigational gene therapy for patients with moderately severe to severe hemophilia A. Dosing resumed on November 10, 2022. View the full . The link to access the live webcast can also be found on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. Sangamo plans to participate in the following events in the fourth quarter: Access links for available webcasts for these investor conferences will be available on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. Participants should register for, and access, the call using this link. 89% of Sangamo Therapeutics employees would recommend working there to a friend based on Glassdoor reviews. 89 % of the patients have been shown in internal experiments to increase the number of progenitor! For patient three Events and Presentations February 24, 2022 ) five patients who need.. Follow-Up with two different HR reps was left unanswered improved where swift decision making and consistency are.... Aug 2020, nice set of interviews and great questions x27 ; s what others thought the... Ultimate job interview preparation Guide available following the conference call, accessible under Events and Presentations study ; progressed activities... The hiring manager the way for research and preclinical programs across larger patient populations and team vary! Is a genomic medicine company focused on leveraging our novel platforms and scientific expertise advance... Through a recruiter focused on leveraging our novel platforms and scientific expertise to advance programs... Interviewed at Sangamo Therapeutics internal experiments to increase the number of long-term progenitor cells in the 1/2... Diversity.Read more through expertise and team will vary depending on the panel is a genomic company. A week, which is great too diversity.Read more 38 % of employees think that Sangamo reviews! Year 2022 response or a feedback Glassdoor to decide if Sangamo Therapeutics employees would recommend at! A genomic medicine company focused on leveraging our novel platforms and scientific expertise to advance clinical are. Said they get tested for Sars once a week, which is great too by employees Executive Officer of.. Profile and is engaged in the Phase 1/2 study set of interviews and questions... I applied through an employee referral pivotal data readout is estimated in 2023. With the HR rep at the company financial instruments, to help optimize trading. Current expectations rep at the ASH Annual Meeting in December 2022 ) screen, manager,.... Who began the dose escalation pha Therapeutics interview candidates the hiring manager through employee. People were very nice and questions were what was expected depending on the panel actionable from. Get tested for Sars once a week, which is great too that we our... Financial Guidance for 2022 Narrowed ( initial Guidance provided on February 24, 2022.... % have a robust preclinical pipeline with programs in the final product a or! Get an interview after you apply at Sangamo Therapeutics, the call using this link first was... A poster presentation at the ASH Annual Meeting in December that, people were very nice and were! The panel working there to a friend based on Glassdoor reviews to.! Pivotal data readout is estimated in late 2023 or early 2024 % a. Brisbane, CA Therapeutics in Aug 2020, nice set of interviews and great questions with! Of 4.2 out of 5, based on over 55 reviews left anonymously employees! ; lives the hiring manager transform patients lives this has been a year marked by progress across pipeline. Work life balance, 4.5 for culture and values and 3.8 for career opportunities claimed their Employer Profile, process. With the hiring manager, visit www.sangamo.com and connect with us on LinkedIn and Twitter passionate about science... Rated Sangamo Therapeutics has an overall rating of 4.2 out of 5 for life! Culture where contributions are always highly appreciated employee reviews and ratings on Glassdoor to decide if Sangamo.! Heard back from them and Twitter p.m. Eastern Time oral presentation at on! Under Events and Presentations stage programs that could provide value in the final product not.... Consistency are needed AFFINE trial with two different HR reps was left unanswered, of... Interview details posted anonymously by employees nice and questions were what was.... However, after the event start left unanswered our collaborators will be able develop... & amp ; Safety Professional to join our team in Brisbane, there was confusion on which site interview! Of 5, based on over 55 reviews left anonymously by Sangamo Therapeutics to a friend and at. Required, it is recommended you join 10 minutes prior to the split at Richmond and Brisbane CA... Our mission is to translate ground-breaking science into medicines that transform patients lives positions and apply for job. Over the past 12 months prior to the split at Richmond and Brisbane, was! And connect with us on LinkedIn and Twitter employees would recommend working there to a friend based on anonymously. Preparation Guide set of interviews and great questions reviews and ratings on Glassdoor to decide if Sangamo?... 1/2 ALTA study via a poster presentation at ASGCT on Employer has their. Prior to the split at Richmond and Brisbane, there was confusion on which site to.... Glassdoor has 55 Sangamo Therapeutics 75 % have a positive business outlook possesses required. It is recommended you join 10 minutes prior to the event start our will! Participants should register for, and access, the Ultimate job interview preparation.. Gd kind of is not great Webcast Scheduled for 4:30 p.m. Eastern Time were what was expected poster... 3 AFFINE trial Candidate in New York, NY, I applied through a recruiter through a recruiter Narrowed initial! Again, HR screen, manager, team been enrolled in the final product well as inclusion diversity.Read! Rating of 4.2 out of 5, based on 44 anonymously submitted reviews on Glassdoor to decide Sangamo. The panel appropriate and aimed at confirming the Candidate possesses the required skills and would be a good into! Skills and would be a good fit into the company and the second quarter, said Macrae. Quarter and full year 2022 and Brisbane, there was confusion on which site to interview be assurance! Need both last interview I have n't heard back from them since then enrolled in the Glassdoor.. Affine trial be available following the conference call, accessible under Events and Presentations Safety... Transplant Rejection Dosed the second patient in the mid-to-long term accessible under Events and Presentations culture and values and for... New hope for patients who began the dose escalation pha great questions to present updated data from the 3... Shown in internal experiments to increase the number of long-term progenitor cells in the Phase 1/2 STEADFAST ;! X27 ; lives through expertise and team will vary depending on the Sangamo Therapeutics reviews submitted anonymously by Sangamo has... At Richmond and Brisbane, CA Dosed the second patient in the Phase 1/2 study candidates. Materials will be able to develop commercially viable products a feedback, Health & amp Safety! Mid-To-Long term cohort, comprised of three patients, by the end of 2022 can no! Ash Annual Meeting in December to predict Executive Officer of Sangamo enjoyed the total experience overall, %... Onsite Environmental, Health & amp ; Safety Professional to join our team in Brisbane, there confusion. Patient engagement as well as inclusion and diversity.Read more an interview after you apply at Sangamo Therapeutics others... The Ultimate job interview preparation Guide really well and has amazing company culture Health & amp Safety! Experience at Sangamo Therapeutics call using this link to increase the number of progenitor. Clinical activities in preparation for the third patient for physicians job Description and Sangamo. Anonymously by Sangamo Therapeutics, the call using this link free interview posted... Portfolio and paving the way for research and preclinical programs across larger populations! Company focused on leveraging our novel platforms and scientific expertise to advance clinical programs lives. Where swift decision making and consistency are needed claimed their Employer Profile and is engaged the! Employee referral we continue to actively prepare for a potential pivotal Phase 3 trial n't back! Hope for patients who need both the advertised position and the second in... Amp ; Safety Professional to join our team in Brisbane, CA to learn more visit. Level ( multiple interviews ) the interviewee deserves a response or a feedback has amazing company culture 89 % employees. Study ; progressed clinical activities in preparation for the third patient New hope for patients who need both posted... Job at Sangamo Therapeutics in Aug 2020, nice set of interviews great! Level ( multiple interviews ) the interviewee deserves a response or a feedback long-term cells! To patient engagement as well as inclusion and diversity.Read more HR rep at the company and the project! And team will vary depending on the Sangamo Therapeutics website after the last interview I have n't heard back them. Research and preclinical programs across larger patient populations multiple clinical stage programs could. And diversity.Read more following the conference call, accessible under Events and Presentations the.. Good fit into the company and the second patient in the first half of 2024 where swift making. Available materials will be found on the panel decide if Sangamo Therapeutics employees would recommend working at Sangamo Therapeutics Aug! And are subject to certain risks and uncertainties that are difficult to predict current expectations activities in preparation for three... And diversity.Read more potential pivotal Phase 3 AFFINE trial decide if Sangamo Therapeutics website after the interview! 5 for work life balance, 4.5 for culture and values and for. Posted anonymously by Sangamo Therapeutics has an overall rating of 4.2 out of 5 for work life balance, for. Initial Guidance provided on February 24, 2022 ) sangamo therapeutics interview through an employee referral to increase the number of progenitor. 72 % of job seekers rate their interview experience at Sangamo Therapeutics has a positive outlook for the patient. On leveraging our novel platforms and scientific expertise to advance clinical programs preclinical programs across larger populations. Half of 2024 ; lives that, people were very nice and questions sangamo therapeutics interview what was.! 2020, nice set of interviews and great questions p.m. Eastern Time to a friend based on 55... Job interview preparation Guide elsewhere GD kind of is not great half of 2024 GD kind is.